Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:BOILNYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOILProShares Ultra Bloomberg Natural Gas$51.46-7.0%$56.35$35.68▼$109.77$214.59M0.142.71 million shs3.22 million shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOILProShares Ultra Bloomberg Natural Gas-6.99%-14.52%-8.25%-31.10%-48.15%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOILProShares Ultra Bloomberg Natural GasN/AN/AN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOILProShares Ultra Bloomberg Natural Gas 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOILProShares Ultra Bloomberg Natural GasN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOILProShares Ultra Bloomberg Natural GasN/AN/A0.00∞N/AN/AN/AN/AN/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOILProShares Ultra Bloomberg Natural GasN/A0.00%N/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOILProShares Ultra Bloomberg Natural GasN/AN/AN/ASYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOILProShares Ultra Bloomberg Natural GasN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipBOILProShares Ultra Bloomberg Natural GasN/ASYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOILProShares Ultra Bloomberg Natural GasN/A4.17 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableSYN, TLOU, BOIL, and IGAS HeadlinesRecent News About These CompaniesEULAR Updates Recommendations for Managing Rheumatoid ArthritisJune 20, 2025 | medscape.comBenefits of early biologic treatment in psoriatic arthritis examined in studiesJune 12, 2025 | medicalxpress.comWhich mesh is best? New research model projects outcomes for abdominal ventral hernia repair patientsJune 4, 2025 | msn.comBioNext: Generics to biologics, India’s moment to leadMay 26, 2025 | msn.comBiologics, Targeted Therapies Best for Acute PsA DactylitisMay 21, 2025 | medscape.comInfection Patterns Matter in Selection of Advanced Therapies for Inflammatory ArthritisMay 16, 2025 | medscape.comAnsa Biotechnologies Rolls Out Early Access Program for Long, Complex Synthetic DNA OrdersMay 11, 2025 | genengnews.comMaxim Group Downgrades Theriva Biologics (TOVX)May 9, 2025 | msn.comAI and Machine Learning as Transformative BioToolsMay 8, 2025 | genengnews.comCytiva and Asimov collaborate on next generation cell line design and process developmentApril 30, 2025 | pharmiweb.comCytiva and Asimov Collaborate on NextGen Cell Line Design and Process DevelopmentApril 29, 2025 | genengnews.comSynthetic Design emerges with $20M and next-gen ADC platformApril 26, 2025 | bioworld.comSeries A financing at Grove BiopharmaApril 25, 2025 | bioworld.com$30 million helps Grove go after hard-to-treat cancersApril 24, 2025 | thepharmaletter.comSynthetic Design Lab Emerges with $20M to Advance Next-Generation ADCsApril 24, 2025 | finance.yahoo.comUS to Phase Out Many Synthetic Food Dyes, Kennedy and FDA Head SayApril 24, 2025 | usnews.comGrove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic ModalityApril 24, 2025 | finance.yahoo.comPharma startup out of Portal's lab raises $30M for cancer-fighting biologicsApril 24, 2025 | chicagobusiness.comThe Increasing Value Of The Synthetic Biology Market By 2035April 17, 2025 | pharmiweb.comSynthetic control arms: full impact yet to be realisedApril 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeNVIDIA Regains Top Spot; FOMO Is Why It Will Continue to RiseBy Thomas Hughes | June 5, 2025View NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to RiseSynopsys Stock Falls on China Ban, But Long-Term Outlook HoldsBy Leo Miller | June 14, 2025View Synopsys Stock Falls on China Ban, But Long-Term Outlook HoldsSYN, TLOU, BOIL, and IGAS Company DescriptionsProShares Ultra Bloomberg Natural Gas NYSEARCA:BOIL$51.46 -3.87 (-6.99%) Closing price 06/24/2025 04:10 PM EasternExtended Trading$51.37 -0.09 (-0.17%) As of 06:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The ProShares Ultra Bloomberg Natural Gas (BOIL) is an exchange-traded fund that is based on the Bloomberg Natural Gas Subindex index. The fund provides 2x the daily return of an index that measures the price performance of natural gas as reflected through publicly traded natural gas futures contracts. BOIL was launched on Oct 4, 2011 and is managed by ProShares.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
